Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia

References

• Dighiero G. Unsolved issues in CLL biology and management. Leukemia17, 2385–2391 (2003).
   PubMed Web of Science ®Google Scholar
• Coiffier B, Tilly H, Pedersen LM et al. HuMax CD20 fully human monoclonal antibody in chronic lymphocytic leukemia: early results from an ongoing Phase I/II clinical trial. Blood106, A135 (2005).
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood94, 1840–1847 (1999).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood94, 1848–1854 (1999).
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med.343, 1910–1916 (2000).
   PubMed Web of Science ®Google Scholar
• Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J. Exp. Med.180, 329–339 (1994).
   PubMed Web of Science ®Google Scholar
• Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol. Today15, 288–294 (1994).
   PubMedGoogle Scholar
• Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med.194, 1639–1647 (2001).
   PubMed Web of Science ®Google Scholar
• Chen L, Apgar J, Huynh L et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood105, 2036–2041 (2005).
   PubMed Web of Science ®Google Scholar
• Messmer BT, Messmer D, Allen SL et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest.115, 755–764 (2005).
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N. Engl. J. Med. 338, 1506–1514 (1998).
   PubMed Web of Science ®Google Scholar
• Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol. J.3, 7–9 (2002).
   PubMedGoogle Scholar
• Tobin G, Thunberg U, Johnson A et al. Chronic lymphocytic leukemias utilizing the VH3–21 gene display highly restricted Vλ2–14 gene usage and homologous CDR3s: implicating recognition of a common antigen epitope. Blood101, 4952–4957 (2003).
   PubMed Web of Science ®Google Scholar
• Ghia P, Guida G, Stella S et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood101, 1262–1269 (2002).
   Google Scholar
• Del Poeta G, Maurillo L, Venditti A et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood98, 2633–2639 (2001).
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med.348, 1764–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Orchard JA, Ibbotson RE, Davis Z et al. ZAP-70 expression by flow cytometry is a good prognostic marker in CLL and a potential surrogate for immunoglobulin VH gene mutations. Lancet363, 105–111 (2004).
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med.351, 893–901 (2004).
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Del Poeta G, Buccisano F et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood108, 853–861 (2006).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Gribben JG, Peterson BL et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J. Clin. Oncol.24, 437–443 (2006).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S. Chronic lymphocytic leukemia: genetics for predicting outcome. Hematology. The EHA Education Program.2(1), 185–190 (2006).
   Google Scholar
• Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. N. Engl. J. Med.21, 1506 (1998).
   Google Scholar
• Flinn IW, Grever MR. Chronic lymphocytic leukaemia. Cancer Treat. Rev.96, 1–13 (1996).
   Google Scholar
• Grever MR, Kopecky KJ, Coltman CA et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol.30, 457– 459 (1988).
   PubMedGoogle Scholar
• Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med.343, 1750–1757 (2000).
   PubMed Web of Science ®Google Scholar
• Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann. Oncol.7, 373–379 (1996).
   PubMed Web of Science ®Google Scholar
• Robak T, Blonski JZ, Kasznicki M et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia – updated results of the multicentre study of 378 patients. Br. J. Haematol.108, 357–368 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson SA, Catovsky D, Child JA et al. Phase I/II evaluation of pentostatin (2´-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest. New Drugs.16, 155–160 (1998).
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood (2006) (Epub ahead of print).
   Google Scholar
• Koel U, Li L, Nowak B. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal [abstract]. Proc. Am. Ass. Cancer Res.38, 2 (1997).
   Google Scholar
• Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood94, 2836–2843 (1999).
   PubMed Web of Science ®Google Scholar
• Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S. Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders [abstract]. Br. J. Haematol.104, 612–613 (1999).
   PubMed Web of Science ®Google Scholar
• Flinn IW, Byrd JC, Morrison C et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood96, 71–75 (2000).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Beran M. Fludarabine and cyclophosphamide therapy in chronic lymphocytic leukemia [abstract]. Blood88, 480 (1996).
   Google Scholar
• Flinn IW, Jemiai Y, Bennett JM et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: E1997 [abstract]. Blood98, 633A (2001).
   Web of Science ®Google Scholar
• Eichhorst B, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood107, 885–891 (2006).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Cortes J et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol.19, 1414–1420 (2001).
   PubMed Web of Science ®Google Scholar
• Morrison VA, Rai KR, Peterson BL et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. J. Clin. Oncol.20, 3878–3884 (2002).
   PubMed Web of Science ®Google Scholar
• Bosch F, Ferrer A, Lopez-Guillermo A et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br. J. Haematol.119, 976–984 (2002).
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kumm E, Grever MR et al. Fludarabine and cyclophosphamide produce a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997. Blood104, A139 (2004).
   Web of Science ®Google Scholar
• Plosker GL, Figgit DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs63, 803–843 (2003).
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood91, 3379–3389 (1998).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood99, 1038–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol.19, 2153–2164 (2001).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol.19, 2165–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Barton JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol.21, 1746–1751 (2003).
   PubMed Web of Science ®Google Scholar
• Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDECC2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm.12, 177–186 (1997).
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res.7, 709–723 (2001).
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood98, 3383–3389 (2001).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood101, 6–14 (2003).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL et al. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood105, 49–53 (2005).
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Irno Consalvo MA et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70 negative chronic lymphocytic leukemia. Cancer104, 2743–2752 (2005).
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Niscola P et al. Consolidation and maintenance therapy with rituximab prolong duration of response both within ZAP-70 positive and negative chronic lymphocytic leukemia. Haematologica91(Suppl. 1), 381 (2006).
   Google Scholar
• Keating MJ, O’Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol.23, 4079–4088 (2005).
   PubMed Web of Science ®Google Scholar
• Wierda W, O’Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol.23, 4070–4078 (2005).
   PubMed Web of Science ®Google Scholar
• Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol.12(6), 574–581 (2000).
   PubMed Web of Science ®Google Scholar
• Domagala A, Kurpisz M. CD52 antigen: a review. Med. Sci. Monit.7(2), 325–331 (2001).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkolm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood100, 768–773 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian HM, Thomas DA et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer98, 2657–2663 (2003).
   PubMed Web of Science ®Google Scholar
• Rai K, Byrd JC, Petersen BL, Larson RA. A Phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901 [abstract]. Blood100, A205–A206 (2002).
   Web of Science ®Google Scholar
• Coutre S, Rai KR, Keating MJ et al. (on behalf of the Campath Study Group). Efficacy and safety of alemtuzumab (Campath-1H) in refractory B-CLL patients treated on a compassionate basis [abstract]. Blood98(11), A365 (2001).
   Google Scholar
• Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol.15, 1567–1574 (1997).
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood99, 3354–3361 (2002).
   Google Scholar
• Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol.20, 3891–3897 (2002).
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol.23, 7024–7031 (2005).
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O’Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood101, 3413–3415 (2003).
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med.347, 452–453 (2002).
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood103, 3278–3281 (2004).
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT et al. Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL). Blood104(11), A101 (2004).
   Google Scholar
• Rai KR, Moore JO, Boyd TE et al. Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (bcl-2 antisense; Genasense; G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood104(11), A100 (2004).
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Coiffier B et al. Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin’s lymphoma. Blood106(11), A683 (2005).
   Google Scholar
• Byrd JC, O’Brien S, Flinn I et al. Safety and efficacy results from a Phase I trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia. Blood104(11), A686 (2004).
   Web of Science ®Google Scholar
• Byrd C, Kipps T, O’Brien S et al. Lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL). Haematologica91(Suppl. 1), 382, (2006).
   Google Scholar
• Milligan DW, Fernandes S, Dasgupta R et al. Autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Results of the MRC Pilot Study. Blood105, 397–404 (2005).
   PubMed Web of Science ®Google Scholar
• Esteve J, Villamor N, Colomer D et al. Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood99, 1873–1874 (2002).
   Google Scholar
• Ritgen M, Lange A, Stilgenbauer S et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood101, 2049–2053 (2003).
   PubMed Web of Science ®Google Scholar
• Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant25, 717–722 (2000).
   PubMed Web of Science ®Google Scholar
• Schetelig J, Thiede C, Bornhauser M et al. Evidence of graft versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell tranplantation: the Cooperative German Tranplant Study Group. J. Clin. Oncol.21, 2747–2753 (2003).
   PubMedGoogle Scholar
• Dreger P, Brand R, Hansz J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneicstem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia17, 841–848 (2003).
   PubMed Web of Science ®Google Scholar
• Itala M, Geisler CH, Kimby E et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Haematol.69, 129–134 (2002).
   Google Scholar
• Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood98, 1326–1331 (2001).
   Google Scholar
• Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood94, 2217–2224 (1999).
   Google Scholar
• Nguyen DT, Amess JA, Doughty H et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur. J. Haematol.62, 76–82 (1999).
   Google Scholar
• Thomas DA, O’Brien S, Giles FJ et al. Single agent rituxan in early stage chronic lymphocytic leukaemia (CLL). Blood98(Suppl. 1), A364, (2001).
   Google Scholar
• Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood100, 3115–3120 (2002).
   Google Scholar
• Lamanna N, Weiss MA, Maslak PG et al. Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL). Blood102(Suppl. 1), 440A (2003).
   Google Scholar